

methoxysalicylaldehyde and isopropanol prior to exposing said protein to said ionizing radiation.

Q1
Conclude
6. (Once Amended) A method according to claim 5 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.

7. (Once Amended) A formulation comprising a solid-state protein and a methoxysalicylaldehyde.

Q2
9. (Once Amended) A formulation according to claim 7 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.

10. (Once Amended) A formulation according to claim 7 wherein said methoxysalicylaldehyde comprises at least about 0.1% by weight of said formulation.

11. (Once Amended) A formulation according to claim 10 wherein said methoxysalicylaldehyde comprises from about 2.9% to about 8.0% by weight of said formulation.

12. (Once Amended) A formulation comprising a solid-state protein, a methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

Q3
14. (Once Amended) A formulation according to claim 12 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.

15. (Once Amended) A formulation according to claim 12 wherein said methoxysalicylaldehyde comprises at least about 0.1% by weight of said formulation, and said 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid comprises at least about 0.1% by weight of said formulation.

16. (Once Amended) A formulation according to claim 15 wherein said methoxysalicylaldehyde comprises from about 2.9% to about 8.0% by weight of said formulation, and said 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid comprises from about 0.1% to about 1.0% by weight of said formulation.